454713-13-4

Basic information

• Product Name: (S)-1-BENZYL-3-N-BOC-AMINOPIPERIDINE
• Synonyms: (S)-1-BENZYL-3-N-BOC-AMINOPIPERIDINE;(S)-(1-BENZYL-PIPERIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER;(R)-3-(BOC-AMINO)-1-BENZYL-PIPERIDINE;(R)-tert-butyl 1-benzylpiperidin-3-ylcarbamate;tert-butyl N-[(3R)-1-benzylpiperidin-3-yl]carbaMate;Carbamic acid, [(3R)-1-(phenylmethyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI);tert-Butyl (R)-(1-benzylpiperidin-3-yl)carbamate
• CAS NO: 454713-13-4
• Molecular Formula: C₁₇H₂₆N₂O₂
• Molecular Weight: 290.4
• Mol File: 454713-13-4.mol

Chemical Properties

• Boiling Point: 400.9 °C at 760 mmHg
• Flash Point: 196.2 °C
• Appearance: /
• Density: 1.07 g/cm³
• Vapor Pressure: 1.23E-06mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.31±0.20(Predicted)
• CAS DataBase Reference: (S)-1-BENZYL-3-N-BOC-AMINOPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-BENZYL-3-N-BOC-AMINOPIPERIDINE(454713-13-4)
• EPA Substance Registry System: (S)-1-BENZYL-3-N-BOC-AMINOPIPERIDINE(454713-13-4)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 454713-13-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
(S)-1-Benzyl-3-N-Boc-aminopiperidine is used as a reagent or an intermediate in organic synthesis for drug discovery. Its utility in creating complex molecules makes it a crucial component in the development of new therapeutic agents.
Used in Scientific Research:
In the field of scientific research, (S)-1-Benzyl-3-N-Boc-aminopiperidine is employed as a laboratory chemical, contributing to the advancement of knowledge in various biochemical and chemical processes. As a laboratory chemical, it requires appropriate handling and safety procedures to mitigate potential risks and hazards.

InChI:InChI=1/C17H26N2O2/c1-17(2,3)21-16(20)18-15-10-7-11-19(13-15)12-14-8-5-4-6-9-14/h4-6,8-9,15H,7,10-13H2,1-3H3,(H,18,20)/t15-/m1/s1

Upstream product

• 309956-78-3 (R)-piperidin-3-ylcarbamic acid tert-butyl ester 
• 100-52-7 benzaldehyde 
• 100-39-0 benzyl bromide 
• 56700-70-0 3-(tert-butoxycarbonylamino)pyridine 
• 1415146-39-2 N-benzyl-3-((tert-butoxycarbonyl)amino)pyridinium bromide 
• 6893-26-1 D-Glutamic acid 
• 34404-28-9 N-[(1,1-dimethylethoxy)carbonyl]-D-glutamic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 62-53-3 aniline 
• 397246-12-7 tert-butyl N-[(2R)-1,5-dihydroxypentan-2-yl]carbamate 
• 168466-84-0 (3R)-1-benzyl-3-aminopiperidine 
• 71962-74-8 Ethyl nipecotate 
• 163343-71-3 (R)-piperidine-3-carboxylic acid ethyl ester*l-tartaric acid 
• 245529-50-4 (R)-1-benzylpiperidine-3-carboxylic acid ethyl ester 

Downstream Products

• 1374239-08-3 (R)-2-(3,5-dichlorophenylamino)-1-(3-(methyl(1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone 
• 1374241-92-5 (R)-2-(3,5-dichlorophenylamino)-1-(3-(methyl(7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone 
• 1374241-90-3 (R)-N-methyl-N-(piperidin-3-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1374241-88-9 N-(1-benzylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1354011-07-6 (R)-1-benzyl-N-methylpiperidine-3-amine 
• 1374239-07-2 (R)-2-(3,5-dichlorophenylamino)-1-(3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone 
• 309956-78-3 (R)-piperidin-3-ylcarbamic acid tert-butyl ester 

Relevant articles and documents

Synthesis method of chiral 3-aminopiperidine and derivatives of 3-aminopiperidine

The invention relates to a synthesis method of chiral 3-aminopiperidine and derivatives of 3-aminopiperidine. According to the synthesis method, R (or S)-piperidine-3-ethyl formate-L (or D)-tartrate is subjected to a hydrazinolysis reaction after being subjected to benzyl protection, and R or S-1-benzyl-3-aminopiperidine is obtained through azidation and Curtius rearrangement. R or S-1-benzyl-3-aminopiperidine is subjected to debenzylation, R or S-3-aminopiperidine can be obtained, R or S-1-benzyl-3-aminopiperidine is subjected to 3-t-butyloxycarboryl protection and debenzylation in sequence,R or S-(3-t-butyloxycarborylamino) piperidine can be obtained, and corresponding salts of R or S-3-aminopiperidine can be obtained through hydrolyzing deprotection of R or S-(3-t-butyloxycarborylamino) piperidine under the acidic condition. The synthesis method of chiral 3-aminopiperidine and the derivatives of 3-aminopiperidine is low in cost, facilitates industrialization and has high optical purity.

JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF

Janus kinase 1 selective inhibitors and pharmaceutical use thereof are provided.

Amino-protected (R) - 3-amino-piperidine preparation method

The invention discloses a preparation method of amino protection (R)-3-amino piperidine, and the preparation method comprises the following steps: (1) in the presence of a first solvent or absence of a solvent, reacting a compound of formula V with benzylamine to obtain a compound of formula VI; (2) in the presence of a second solvent, performing catalytic hydrogenation of the compound of formula VI to remove benzyl to obtain the amino protection (R)-3-amino piperidine. According to the method, the defects of use of expensive metal catalysts and use of high-pressure hydrogenation and various splitting for synthesis of a chiral amino piperidine ring can be avoided, at the same time, the synthetic route is short, the process is simple, the yield is high, and the method is suitable for industrial mass production.

Asymmetric Hydrogenation of 3-Substituted Pyridinium Salts

The use of an equivalent amount of an organic base leads to high enantiomeric excess in the asymmetric hydrogenation of N-benzylated 3-substituted pyridinium salts into the corresponding piperidines. Indeed, in the presence of Et3N, a Rh-JosiPhos catalyst reduced a range of pyridinium salts with ee values up to 90 %. The role of the base was elucidated with a mechanistic study involving the isolation of the various reaction intermediates and isotopic labeling experiments. Additionally, this study provided some evidence for an enantiodetermining step involving a dihydropyridine intermediate.

HETEROCYCLIC TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.

Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).